The 2024 update on heart failure (HF) highlights major advancements in management, including the recommendation of sodium-glucose co-transporter-2 (SGLT2) inhibitors and finerenone for HF prevention in diabetic chronic kidney disease (CKD) patients. SGLT2 inhibitors are now recommended for all left ventricular ejection fraction (LVEF) ranges, with quadruple therapy showing benefits in HF with reduced ejection fraction (HFrEF). The 'high-intensity care' strategy, involving rapid titration and frequent monitoring, improved outcomes in the STRONG-HF trial. Vericiguat may be needed for patients with worsening HF. Semaglutide reduced body weight and improved quality of life in HF with preserved ejection fraction (HFpEF) patients. Further data are needed to support the addition of acetazolamide or hydrochlorothiazide to standard diuretic regimens. The PUSH-AHF trial supported natriuresis-guided diuretic therapy. New evidence includes specific drugs for cardiomyopathies (mavacamten for hypertrophic cardiomyopathy, tafamidis for transthyretin cardiac amyloidosis), device therapies, and percutaneous treatment of valvulopathies. Gender differences in HF prevalence, pathophysiology, and treatment are significant, with women experiencing greater survival loss but lower mortality. Inflammation plays a central role in HF pathophysiology, with inflammatory biomarkers linked to disease severity. Autonomic nervous system dysregulation contributes to HF progression. Comorbidities like hypertension, diabetes, and kidney dysfunction are common in HF patients and affect outcomes. SGLT2 inhibitors reduce cardiovascular mortality and improve kidney outcomes in patients with CKD. Coronary artery disease (CAD) is more prevalent in HFrEF than HFpEF. Aortic valve disease is more common in HFpEF, with severe aortic stenosis increasing CV mortality. Atrial fibrillation (AF) can exacerbate HF, with catheter ablation showing benefits in some cases. Pulmonary hypertension is common in HF, with selexipag reducing morbidity and mortality. Cancer is associated with higher mortality in HF patients. Anaemia and iron deficiency are significant prognostic factors, with IV iron supplementation recommended in symptomatic HFrEF or HFmrEF patients. SGLT2 inhibitors improve haemoglobin levels, even in patients with iron deficiency. Infections and COVID-19 have impacted HF management, with vaccination recommended for all HF patients. Early diagnosis of HF is facilitated by natriuretic peptides and machine learning. Biomarkers like NT-proBNP and hs-TnT are important for prognosis. Imaging techniques like global longitudinal strain (GLS) are valuable for assessing HF. Machine learning improves HF diagnosis and management. Specific causes of HF include cardiomyopathies, cardiac amyloidosis, and peripThe 2024 update on heart failure (HF) highlights major advancements in management, including the recommendation of sodium-glucose co-transporter-2 (SGLT2) inhibitors and finerenone for HF prevention in diabetic chronic kidney disease (CKD) patients. SGLT2 inhibitors are now recommended for all left ventricular ejection fraction (LVEF) ranges, with quadruple therapy showing benefits in HF with reduced ejection fraction (HFrEF). The 'high-intensity care' strategy, involving rapid titration and frequent monitoring, improved outcomes in the STRONG-HF trial. Vericiguat may be needed for patients with worsening HF. Semaglutide reduced body weight and improved quality of life in HF with preserved ejection fraction (HFpEF) patients. Further data are needed to support the addition of acetazolamide or hydrochlorothiazide to standard diuretic regimens. The PUSH-AHF trial supported natriuresis-guided diuretic therapy. New evidence includes specific drugs for cardiomyopathies (mavacamten for hypertrophic cardiomyopathy, tafamidis for transthyretin cardiac amyloidosis), device therapies, and percutaneous treatment of valvulopathies. Gender differences in HF prevalence, pathophysiology, and treatment are significant, with women experiencing greater survival loss but lower mortality. Inflammation plays a central role in HF pathophysiology, with inflammatory biomarkers linked to disease severity. Autonomic nervous system dysregulation contributes to HF progression. Comorbidities like hypertension, diabetes, and kidney dysfunction are common in HF patients and affect outcomes. SGLT2 inhibitors reduce cardiovascular mortality and improve kidney outcomes in patients with CKD. Coronary artery disease (CAD) is more prevalent in HFrEF than HFpEF. Aortic valve disease is more common in HFpEF, with severe aortic stenosis increasing CV mortality. Atrial fibrillation (AF) can exacerbate HF, with catheter ablation showing benefits in some cases. Pulmonary hypertension is common in HF, with selexipag reducing morbidity and mortality. Cancer is associated with higher mortality in HF patients. Anaemia and iron deficiency are significant prognostic factors, with IV iron supplementation recommended in symptomatic HFrEF or HFmrEF patients. SGLT2 inhibitors improve haemoglobin levels, even in patients with iron deficiency. Infections and COVID-19 have impacted HF management, with vaccination recommended for all HF patients. Early diagnosis of HF is facilitated by natriuretic peptides and machine learning. Biomarkers like NT-proBNP and hs-TnT are important for prognosis. Imaging techniques like global longitudinal strain (GLS) are valuable for assessing HF. Machine learning improves HF diagnosis and management. Specific causes of HF include cardiomyopathies, cardiac amyloidosis, and perip